Aktienanalyse zu Tempest Therapeutics Inc (TPST)

KI-Analyse of Tempest Therapeutics Inc (TPST)

Verkaufen

Tempest Therapeutics Inc (TPST) is not a good buy right now. The current price is $0.3801, which is significantly lower than the 52-week high of $10.33, indicating a drastic decline of 96.12% over the past year. Additionally, the RSI is at a very low 10.575, suggesting extreme oversold conditions, but this could reflect deeper underlying issues rather than a buying opportunity. The company has reported a net income loss of $27,696,000 for Q1 2026, which raises concerns about its financial stability. The recent financing news has not positively impacted the stock, as it fell 4.60% after announcing a private placement to raise $2.5 million, reflecting market skepticism about its future prospects. The main risk is the company's ongoing losses and reliance on external funding, which could further dilute shareholder value.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Tempest Therapeutics Inc (TPST) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -1.06.

Erwartetes KGV

Überbewertet

5J-Durchschnitt P/E

-1.06

Aktuelles P/E

0.00

Überbewertet

-0.32

Unterbewertet

-1.80

Erwartetes EV/EBITDA

Fair bewertet

5J-Durchschnitt EV/EBITDA

-0.48

Aktuelles EV/EBITDA

0.00

Überbewertet

0.34

Unterbewertet

-1.30

Erwartetes KUV

Stark unterbewertet

5J-Durchschnitt P/S

0.00

Aktuelles P/S

0.00

Überbewertet

0.00

Unterbewertet

0.00

Alphio-AI-Kursszenarien für TPST

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%TPST

$7.28

Szenariopreis

B

Basis

Basis · 50%TPST

$6.05

Szenariopreis

B

Bärisch

Bärisch · 25%TPST

$5.75

Szenariopreis

TPST FAQ – beantwortet von Alphio AI

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company moving towards late-stage development with a portfolio of targeted and immune-mediated product candidates with the potential to be first-in-class to treat a range of cancers. Its programs range from early research to the lead program, amezalpat, a pivotal study in first-line hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, is a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 (PGE2), a pathway implicated in multiple cancers. Its development strategy for TPST-1495 includes evaluation in familial adenomatous polyposis (FAP), a rare genetic disorder that increases the risk of gastrointestinal cancers. Its pipeline also includes TPST-2003, TPST-2206, TPST-3003, and TPST-3206. TPST-2003 is a new dual-targeting CD19/BCMA CAR-T asset. TPST-2206 is a dual-targeting CD70/CD70 CAR-T for renal cell carcinoma. TPST-3206 is an allogeneic dual-targeting CD70/CD70. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Tempest Therapeutics Inc (TPST) is not a good buy right now. The current price is $0.3801, which is significantly lower than the 52-week high of $10.33, indicating a drastic decline of 96.12% over the past year. Additionally, the RSI is at a very low 10.575, suggesting extreme oversold conditions, but this could reflect deeper underlying issues rather than a buying opportunity. The company has reported a net income loss of $27,696,000 for Q1 2026, which raises concerns about its financial stability. The recent financing news has not positively impacted the stock, as it fell 4.60% after announcing a private placement to raise $2.5 million, reflecting market skepticism about its future prospects. The main risk is the company's ongoing losses and reliance on external funding, which could further dilute shareholder value.